Help us learn how the immune system of healthy individuals and patients with compromised immune systems respond to an inactivated vaccine.
Join our study today.
This study will help us to better understand how the immune system of healthy adults respond to an FDA-approved inactivated rabies vaccine. This is an inactivated vaccine, so there is no risk of getting rabies infection from the vaccine.
Our bodies produce antibodies when they sense foreign cells. The study will be comparing the antibodies produced after vaccination in healthy volunteers and participants with compromised immune systems from cancer and cancer therapies.
People who agree to join the study will be asked to attend up to nine visits over approximately 6 months, although only the two vaccination visits are required to be in-person.
Volunteers who agree to participate will be asked to provide nine blood samples throughout the study participation. Two of these samples will be collected during the vaccination visits. Blood draws will also be done at 1, 2 and 4-weeks post each vaccination, and one additional draw six months after the initial vaccinations. Volunteers will be given the option to self-collect blood from home using a Tasso device.
Volunteers will be given two vaccinations scheduled 6-10 weeks apart. The first vaccination is given at the initial clinic vsit. The second vaccination will be scheduled 6-10 weeks after the first vaccination. There will be blood draws prior to each vaccination, and we will still ask you to stay for 15 minutes post-vaccination for observation. The follow-up schedule for the second vaccination will be the same as for the initial visit.
Dr. Joshua Hill is a physician who specializes in the treatment of infectious diseases in cancer patients, solid organ transplant patients and others with weakened immune systems. His research includes clinical trials of new medicines to prevent or treat infections in such patients. Dr. Hill’s epidemiological research focuses on infections in immunocompromised hosts, including those receiving new therapies such as CAR T cells.